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Modern research in the therapy of oncological diseases testify an essential role of glutamic acid derivatives in cancer pathogenesis. Substances competitively inhibiting glutamate in the interaction with АМРА-and NMDA-receptors will be most likely very useful in oncopathology treatment [1, 2] . Therefore, a promising area of pharmaceutical science is further study of [1, 2, 4] triazolo [4,3-a] pyrazines, which exhibit the pharmacological effects mentioned above, as well as creation of medicines on their basis.
With the help of the computer programme PASS (Prediction of Activity Spectra for Substances) [3] , which enable to estimate the pharmacological effect, the mechanism of action and specific toxicity of a substance, we carried out the investigation of the base of N 7 -aryl- [1, 2, 4] triazolo [4,3-a] pyrazines derivatives with alkyl substituents in position 3 previously synthesized [4] . Computational results indicate a high potential of cytotoxic, membrane-stabilizing, cerebroprotective, cardioprotective activity of the compounds obtained.
Variation of substituents in molecules with the same heterocyclic structure can affect the ligand-receptor interaction; it can be relevant in therapy of not only oncopathologies, but many diseases associated with the protein-receptor competitive antagonism.
On the basis of analysis of the chemical potential of [1, 2, 4] triazolo [4,3-a] pyrazine structure, which is bioisosteric analogue of nucleic acids, the most promising randomization points of this basic structure have been determined and the synthetic transformation schemes that are suitable for focused combinatorial libraries construction have been developed.
The scheme of [1, 2, 4] triazolo [4,3-a] pyrazines synthesis that is used in organic synthesis the most frequently starts from 2,3-dichloropyrazine and consists in cyclization of 2-chloro-3-hydrazinopyrazine obtained under the action of acid halides of carbonic acid with hydrolysis of intermediate 8-chloro [1, 2, 4] triazolo [4,3-a] pyrazine and subsequent N-alkylation [5] . The principal lack of this method is a limited set of substituents in position 7 of the cyclization product. In our previous work approaches to N 7 -substituted [1, 2, 4] triazolo [4,3-a] pyrazines with alkyl and aryl substituents in position 7 were discussed. The aim of the present paper is the use of a wide range of carbonyl reagents for modification of position 3 in the target [1, 2, 4] triazolo [4,3-a] pyrazines by various substituents.
Results and Discussion
Earlier we reported that we had developed the scheme of the synthesis of the target For this purpose the scheme of interaction of N 1 -aryl/benzyl-3-hydrazinopyrazin-2-ones 4{1-4} with the corresponding carbonic acids 1{1-4} has been suggested. However, low electrophility of the carboxylic group hinders the effective course of the reaction. Hence, for the carboxylic group activation we suggest to use carbonyldiimidazole (CDI) 2 in anhydrous DMFA in the molar ratio of 1:1 (Scheme). 
